Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708805 | 1.00 | CYP19A1 (0.40) | CYP19A1MAOBCYP3A4GAAMEN1 | |
| SCHEMBL17708950 | 0.84 | CYP19A1 (0.43) | CYP19A1MAOBCYP3A4MEN1ALDH1A1 | |
| SCHEMBL17708951 | 0.84 | CYP19A1 (0.43) | CYP19A1MAOBCYP3A4MEN1ALDH1A1 | |
| SCHEMBL17708769 | 0.82 | CYP19A1 (0.56) | CYP19A1MAOBCYP3A4GAA | |
| SCHEMBL14341913 | 0.72 | MAPT (0.46) | CYP19A1MAOBCYP3A4MEN1ALDH1A1 | |
| SCHEMBL5177217 | 0.71 | MAPT (0.49) | CYP19A1MAOBCYP3A4GAAMEN1 | |
| SCHEMBL5177223 | 0.71 | MAPT (0.49) | CYP19A1MAOBCYP3A4GAAMEN1 | |
| Methyl Alcohol SCHEMBL17761488 | 0.70 | HPGD (0.37) | CYP19A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL17708867 | 0.69 | GAA (0.37) | CYP19A1GAAMAPT | |
| SCHEMBL874411 | 0.68 | KDM4E (0.48) | CYP19A1CYP3A4GAAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| EP-3212189-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | AbbVie S.À.R.L. (LU) | 2017-09-06 | — | — | EP | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| WO-2016069757-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CYP19A1 994/4885MAOB 3188/4885CYP3A4 227/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CYP19A1 994/4885MAOB 3188/4885CYP3A4 227/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | CYP19A1 994/4885MAOB 3188/4885CYP3A4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.